StemCyte International Company Description

StemCyte International, Ltd. operates cord blood cell banks in the United States and Taiwan.

It supplies cord blood to medical centers for transplantation in the treatment of blood system diseases; and provides cord blood supply, mononuclear cell supply, and immune cell supply services.

The company also develops cord blood to treat COVID-19 syndrome and acute ischemic stroke; and CB201, an immune cell drug.

In addition, it offers cord blood storage, immune cell storage, and cord blood cell bank transplant cell services.

The company was founded in 2013 and is based in Taipei, Taiwan.

StemCyte International, Ltd.

Country	Cayman Islands
Founded	2013
Industry	Miscellaneous Health And Allied Services, Not Elsewhere Classified

Contact Details

Address: No. 508, Zhongxiao E. Rd. Taipei, 115 Taiwan
Phone	886 2 2601 3013
Website	stemcytebio.com

Stock Details

Ticker Symbol	4178
Exchange	Taipei Exchange
Fiscal Year	January - December
Reporting Currency	TWD
SIC Code	8090